Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367846 | 0.89 | HPGD (0.54) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL17283083 | 0.89 | PFKFB3 (0.58) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL15924211 | 0.88 | HPGD (0.60) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL2367593 | 0.87 | HPGD (0.53) | HPGDSMN1; SMN2CYP1A2CYP19A1POLB | |
| SCHEMBL2367880 | 0.86 | CYP19A1 (0.53) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL2368342 | 0.86 | POLB (0.53) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL21332831 | 0.85 | HPGD (0.54) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL18457359 | 0.85 | CYP1A2 (0.73) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT | |
| SCHEMBL2368039 | 0.84 | KDM4E (0.50) | HPGDSMN1; SMN2CYP19A1HTTKLKB1 | |
| SCHEMBL2368340 | 0.84 | HPGD (0.50) | HPGDSMN1; SMN2CYP1A2CYP19A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-12-17 | — | — | US | disclosed |
| EP-3514158-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-07-02 | — | — | US | disclosed |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-07-02 | — | — | US | disclosed |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2014120800-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2368887-B1 | 1, 2, 3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20130281499-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2013-10-24 | — | — | US | disclosed |
| US-20130203821-A1 | Pyridine Compounds for Controlling Invertebrate Pests II | BASF SE (DE) | 2013-08-08 | — | — | US | disclosed |
| EP-2616458-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS II | BASF SE (DE) | 2013-07-24 | — | — | EP | disclosed |
| US-8486977-B2 | 1,2,3-triazole derivatives for use as stearoyl-CoA desaturase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2012034960-A1 | PYRIDINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS II | BASF SE (DE) | 2012-03-22 | — | — | WO | disclosed |
| EP-2368887-A1 | 1, 2, 3-triazole derivatives for use as stearoyl-COA desaturase inhibitors | Glaxosmithkline LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2008130321-A2 | NOVEL N-TETRAHYDRONAPHTALENE OR 5-HETEROCYCLYL-CHROMANE OR 8-HETEROCYCLYL-TETRAHYDRONAPHTALENE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
| US-20130203821-A1 | Pyridine Compounds for Controlling Invertebrate Pests II | GRIN2A, NR2C2, GRIA2 | HPGD 2129/4885SMN1; SMN2 1356/4885CYP1A2 59/4885 |
| US-20100297054-A1 | 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FASN | HPGD 592/4885SMN1; SMN2 2403/4885CYP1A2 217/4885 |
| US-10441571-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
| US-20130281499-A1 | COMPOUNDS | CYP11B2, SCD, CYP11B1 | HPGD 719/4885SMN1; SMN2 771/4885CYP1A2 53/4885 |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | HPGD 699/4885SMN1; SMN2 913/4885CYP1A2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.